Learning Objectives:

  1. Review adjuvant therapy for resected cholangiocarcinoma and discuss multimodal management of locally advanced disease Discuss the effect of antibiotic treatment on response and survival with checkpoint inhibitor therapy
  2. Review systemic therapies for metastatic disease
  3. Explore emerging therapeutic targets with regards to targeted genomic agents and the role of immunotherapy



  1. Discuss the use of immune checkpoint inhibitors in treatment of HCC Review the literature on the long term consequences of these metabolic derangements, including effects on physical and emotional health outcomes
  2. Discuss challenges in treating recurrent HCC after liver transplantation
  3. Discuss novel strategies under investigation for treatment of HCC
Session date: 
07/01/2019 - 12:00pm to 1:00pm CDT
5841 South Maryland Avenue, MC2115
MC2115 HemOnc Conference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Natalie M. Reizine, MD and Sherin J. Rouhani, MD, PhD